Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA grants priority review to Alexion's ERT asfotase alfa

This article was originally published in Scrip

Executive Summary

The FDA has granted a priority review to Alexion's enzyme replacement therapy asfotase alfa as a treatment for patients with infantile- and juvenile-onset hypophosphatasia (HPP), a chronic and progressive ultra-rare genetic metabolic disease characterized by defective bone mineralization, which can lead to destruction and deformity of bones, profound muscle weakness, seizures, respiratory failure and premature death.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC027969

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel